TABLE 5.
Efficacy of GSK2556286 combined with various 2- and 3-drug combinations of B, Pa, and L in a BALB/c mouse model of TB
| Regimen | Mean lung log10 CFU ± SD |
Proportion of mice relapsing after treatment fora: |
||||
|---|---|---|---|---|---|---|
| Day 0 | Mo 1 | Mo 2 | 2 mo | 3 mo | 4 mo | |
| Untreated | 7.30 ± 0.10 | |||||
| RHZ | 5.12 ± 0.14 | 2.55 ± 0.07 | NT | NT | 7/15 | |
| BPaL | 3.10 ± 0.17 | 0.00 ± 0.00 | 4/15 | 1/15 | NT | |
| BPa+GSK2556286 | 3.77 ± 0.36 | 0.27 ± 0.54 | 5/15 | 1/15 | 0/15 | |
| BL+GSK2556286 | 4.16 ± 0.34 | 1.91 ± 0.33 | 14/15 | 2/14b | 1/14b | |
| PaL+GSK2556286 | 5.19 ± 0.19 | 2.87 ± 0.34 | 15/15 | 15/15 | 11/15 | |
| BPaL+GSK2556286 | 2.75 ± 0.36 | 0.00 ± 0.00 | 2/15 | 0/15 | NT | |
a
NT, not tested.
b
One of 15 mice died due to a gavage accident and could not be assessed for relapse.